Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Aktuelle Urol ; 48(4): 314-328, 2017 Aug.
Artículo en Alemán | MEDLINE | ID: mdl-28609792

RESUMEN

Background Adjuvant Bacillus Calmette-Guérin (BCG) intravesical instillation is the recommended standard treatment in patients with high-risk non-muscle-invasive bladder cancer (NMIBC). However, a significant proportion of patients fail treatment, and radical cystectomy (RC) is the subsequent gold standard. On the other hand, there is an unmet need for conservative alternatives for patients who are unfit or unwilling to undergo surgery. This study aimed to identify conservative treatment options in NMIBC patients after BCG failure. Material and Methods We performed a systematic search in the databases Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE and EMBASE, including all randomised controlled trials (RCTs), quasi-RCTs and single-arm studies, in which patients with NMIBC were treated with second-line intravesical or systemic therapy after BCG failure. A minimum of eight patients were included in each treatment arm. Full papers were restricted to English language. Literature research and data analysis were assessed independently by two reviewers. Data on treatment response, recurrence, time to recurrence, progression and rate of cystectomy were collected and analysed. Results This systematic review included 42 publications with a total of 3521 patients (2371 BCG failures). Valrubicin, taxanes, gemcitabine, combination chemotherapy, thermochemotherapy, photodynamic therapy, combination of BCG and interferon and immunotherapies or targeted therapies were identified as conservative treatment options. For taxanes, gemcitabine and thermochemotherapy there is the highest evidence for a clinical meaningful response with minor toxicities. Conclusions Despite some promising response rates for taxanes, gemcitabine or thermochemotherapy, an evidence-based recommendation for treatment options superior to RC in patients failing BCG therapy cannot be made. The definition of BCG failure is still inconsistent and heterogeneous outcomes in patients with BCG failure have been reported. In order to identify effective conservative therapy options in patients failing BCG therapy, prospective trials with a standardised trial design are needed.


Asunto(s)
Vacuna BCG , Tratamiento Conservador , Neoplasias de la Vejiga Urinaria , Adyuvantes Inmunológicos , Antimetabolitos Antineoplásicos/uso terapéutico , Vacuna BCG/farmacología , Desoxicitidina/análogos & derivados , Desoxicitidina/uso terapéutico , Farmacorresistencia Viral , Humanos , Inmunoterapia , Ensayos Clínicos Controlados Aleatorios como Asunto , Neoplasias de la Vejiga Urinaria/terapia , Gemcitabina
2.
BJU Int ; 106(11): 1668-72, 2010 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-20518761

RESUMEN

OBJECTIVE: To evaluate the efficacy and safety of a transobturator retroluminal repositioning sling suspension in the treatment of male stress urinary incontinence (SUI) after prostate surgery. PATIENTS AND METHODS: In 118 men with SUI after prostatic surgery, a transobturator retroluminal repositioning sling suspension was implanted. Patients were evaluated including: complete history and physical examination, 24-h pad test, a questionnaire (International Consultation on Incontinence Questionnaire, Short-Form), urodynamic evaluation and endoscopy. The surgical technique was described previously. The findings before and at 1 year after sling placement were compared. RESULTS: At the 12-month follow-up, 73.7% of the men were cured, 16.9% were improved, and 9.3% were still incontinent. After sling placement the daily pad use decreased significantly (P < 0.001), while the ICIQ-SF improved significantly (P < 0.01). The detrusor voiding pressure, postvoid residual urine volume and maximal flow rates remained unchanged, while the Valsalva leak-point pressure improved significantly (P < 0.01). In 19.5% of the men, there was transient scrotal pain or perineal discomfort. In 5.1% of the men, postoperative urinary retention occurred but resolved spontaneously after a few weeks of catheter placement. In 1.7% of the men adductor pain was reported, which resolved spontaneously. There were no major complications. CONCLUSION: The transobturator retroluminal repositioning sling suspension for the treatment of male SUI is effective and safe with a low complication rate after 1 year of follow-up.


Asunto(s)
Prostatectomía/efectos adversos , Neoplasias de la Próstata/cirugía , Cabestrillo Suburetral , Incontinencia Urinaria de Esfuerzo/cirugía , Anciano , Métodos Epidemiológicos , Humanos , Masculino , Persona de Mediana Edad , Neoplasias de la Próstata/complicaciones , Calidad de Vida , Cabestrillo Suburetral/efectos adversos , Resultado del Tratamiento , Incontinencia Urinaria de Esfuerzo/etiología , Urodinámica
3.
Indian J Urol ; 26(4): 577-9, 2010 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-21369394

RESUMEN

New and minimal invasive single incision mid-urethral sling procedures are available for treating female stress urinary incontinence. We present a case of a massive retropubic hematoma in a patient with a "corona mortis" artery following a minimal invasive sling procedure. The patient was managed conservatively. The hematoma resolved and the patient remained continent after surgery. Nature and symptoms of sling-related complications should prompt the diagnosis and appropriate postoperative management. One should always be conscious of possible vascular anomalies that might lead to unexpected complications.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA